New cell therapy trial targets Hard-to-Treat heart amyloidosis
NCT ID NCT07504289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment for people with a rare disease called light-chain cardiac amyloidosis that has come back or not responded to other treatments. The treatment uses specially engineered immune cells (CAR-NK cells) from donated umbilical cord blood to target and attack the harmful proteins in the heart. The trial will enroll 36 adults aged 18-75 and will check for safety and how well the therapy works over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-NK cells (immune cells engineered to target BCMA and CD19 proteins)
- What this could lead to
- If it works, this could offer a safer, faster-to-make cell therapy option for patients with this rare and serious heart condition.
- What could go wrong
- This is an early phase 1/2 trial with only 36 participants, so results are preliminary. There are risks of serious side effects like cytokine release syndrome or nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT-CHAIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.